Dapagliflozin treatment and cardiovascular outcome in RBP4/TTR^Val30Met (transthyretin cardiac amyloidosis) mice.

ABSTRACT:

Aims

Whether sodium-glucose co-transporter 2 inhibitors are effective for heart failure caused by ATTR-CA (transthyretin cardiac amyloidosis) remains uncertain. The aim of this study is to investigate the cardiovascular prognosis in ATTR-CA mice model with dapagliflozin treatment.

Methods and results

Humanized RBP4/TTR^Val50Met and RBP4/TTR mice models were constructed with clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) techniques and multiple generations breeding. A total of 6 RBP4/TTR mice received placebo treatment, when 12 RBP4/TTR^Val50Met received dapagliflozin (1 mg/kg/day, 6 mice) and placebo (6 mice) treatment. Fasting glucose, intraperitoneal glucose tolerance test, and plasma brain natri

SUBMITTER: Li Z 

PROVIDER: S-EPMC10804162 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature